☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
x4 pharmaceuticals
X4 Pharmaceuticals’ Xolremdi Receives the US FDA’s Approval for the Treatment of WHIM Syndrome
April 30, 2024
X4 Pharmaceuticals to Present P-III Trial (4WHIM) Results of Mavorixafor for the Treatment of WHIM Syndrome at CIS 2023
May 17, 2023
PharmaShots Interview: X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficien...
May 3, 2022
Pharmashots Interview: Paula Ragan Shares Insights on the Data of Mavorixafor in Combination with Ibrutinib Presented at 2021 EHA...
September 3, 2021
Load more...
Back to Home